抗肿瘤坏死因子α治疗的一种罕见不良反应：结节病。
A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis.
作者信息
Mengi Gönen, Göğüş Feride
机构信息
Department of Rheumatology, Muğla Sıtkı Koçman University, Education And Research Hospital, Muğla, Turkey.
Department of Physical Medicine and Rehabilitation, Medical Faculty of Gazi University, Ankara, Turkey.
出版信息
Arch Rheumatol. 2017 Feb 12;32(1):67-70. doi: 10.5606/ArchRheumatol.2017.6055. eCollection 2017 Mar.
Abstract
Anti-tumor necrosis factor alpha (anti-TNF-a) therapy has been widely used for the management of rheumatologic diseases. The most frequent adverse effects of anti-TNF-a therapy are infections and malignancies while sarcoidosis is a rare condition. On the other hand, anti-TNF-a therapy has been used in the treatment of sarcoidosis. Elucidation of this paradoxical issue is unclear. In this article, we report an ankylosing spondylitis patient who was diagnosed as sarcoidosis during the period of etanercept usage. Sarcoidosis as a possible adverse effect should be kept in mind during anti-TNF-a therapy.
摘要
抗肿瘤坏死因子α（抗TNF-α）疗法已广泛用于治疗风湿性疾病。抗TNF-α疗法最常见的不良反应是感染和恶性肿瘤，而结节病则是一种罕见病症。另一方面，抗TNF-α疗法已用于结节病的治疗。这种矛盾问题的阐释尚不清楚。在本文中，我们报告了一名强直性脊柱炎患者，该患者在使用依那西普期间被诊断为结节病。在抗TNF-α治疗期间应牢记结节病可能作为一种不良反应。
相似文献
1
A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis.抗肿瘤坏死因子α治疗的一种罕见不良反应：结节病。
Arch Rheumatol. 2017 Feb 12;32(1):67-70. doi: 10.5606/ArchRheumatol.2017.6055. eCollection 2017 Mar.
2
Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept.阿达木单抗诱导的结节病在用依那西普治疗后病情未进展。
Z Rheumatol. 2017 May;76(4):372-374. doi: 10.1007/s00393-016-0262-4.
3
Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.炎症性风湿性疾病抗TNF-α治疗期间发生的结节病：两例报告。
Clin Exp Rheumatol. 2008 May-Jun;26(3):471-5.
4
Pustular eruption induced by etanercept in a patient with ankylosing spondylitis: a rare side effect.强直性脊柱炎患者使用依那西普诱发脓疱性皮疹：一种罕见的副作用。
North Clin Istanb. 2015 Jul 24;2(3):231-235. doi: 10.14744/nci.2015.95914. eCollection 2015.
5
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎：系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
6
Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis.强直性脊柱炎患者在抗TNF治疗下出现的肌肉结节病
Joint Bone Spine. 2018 Dec;85(6):769. doi: 10.1016/j.jbspin.2018.05.001. Epub 2018 May 19.
7
Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.肿瘤坏死因子α拮抗剂治疗过程中皮肤结节病的发展。
Australas J Dermatol. 2012 Nov;53(4):e87-90. doi: 10.1111/j.1440-0960.2011.00863.x. Epub 2012 Feb 16.
8
The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.泰国人群中抗肿瘤坏死因子药物的感染谱：一项基于大学医院的回顾性研究。
Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.
9
Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature.肿瘤坏死因子α阻滞剂诱发的幼年类风湿关节炎合并红皮病型结节病：一例报告及文献复习
Ann Dermatol. 2017 Feb;29(1):74-78. doi: 10.5021/ad.2017.29.1.74. Epub 2017 Feb 3.
10
Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.抗肿瘤坏死因子α制剂治疗皮肤结节病的疗效与耐受性：一项针对46例患者的法国研究
JAMA Dermatol. 2017 Jul 1;153(7):681-685. doi: 10.1001/jamadermatol.2017.1162.
引用本文的文献
1
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.关注抗肿瘤坏死因子 (TNF)-α 相关自身免疫性疾病。
Int J Mol Sci. 2023 May 3;24(9):8187. doi: 10.3390/ijms24098187.
2
Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature.与培塞利珠单抗治疗类风湿关节炎相关的系统性结节病：一例报告及文献复习
Intern Med. 2020 Aug 15;59(16):2015-2021. doi: 10.2169/internalmedicine.4275-19. Epub 2020 May 8.
本文引用的文献
1
A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.抗肿瘤坏死因子α疗法治疗克罗恩病的安全性评估。
Expert Opin Drug Saf. 2016;15(4):493-501. doi: 10.1517/14740338.2016.1145653. Epub 2016 Feb 19.
2
Acute kidney injury due to renal sarcoidosis during etanercept therapy: a case report and literature review.依那西普治疗期间肾结节病所致急性肾损伤：一例报告及文献复习
Intern Med. 2015;54(9):1131-4. doi: 10.2169/internalmedicine.54.4188. Epub 2015 May 1.
3
Adverse effects of TNF inhibitors in SpA: are they different from RA?AS 中 TNF 抑制剂的不良反应：与 RA 有何不同？
Best Pract Res Clin Rheumatol. 2014 Oct;28(5):747-63. doi: 10.1016/j.berh.2014.10.001. Epub 2014 Oct 31.
4
Lung sarcoidosis in etanercept treated rheumatoid arthritis patient: a case report and review of the literature.依那西普治疗的类风湿关节炎患者并发肺部结节病：一例报告及文献复习
Case Rep Rheumatol. 2014;2014:358567. doi: 10.1155/2014/358567. Epub 2014 Jul 3.
5
Systemic sarcoidosis induced by etanercept: first Brazilian case report.依那西普诱发的系统性结节病：首例巴西病例报告。
An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):197-9. doi: 10.1590/abd1806-4841.20132588.
6
Paradoxical effects of anti-TNF-α agents in inflammatory diseases.抗TNF-α药物在炎症性疾病中的矛盾效应。
Expert Rev Clin Immunol. 2014 Jan;10(1):159-69. doi: 10.1586/1744666X.2014.866038. Epub 2013 Dec 10.
7
Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.类风湿关节炎患者应用 TNF 拮抗剂后引发的肺结节病：病例报告及文献复习。
Arch Bronconeumol. 2011 Apr;47(4):208-12. doi: 10.1016/j.arbres.2010.05.011. Epub 2010 Jul 17.
8
Targeting the TNF-alpha pathway in sarcoidosis.靶向结节病中的 TNF-α 通路。
Expert Opin Ther Targets. 2010 Jan;14(1):21-9. doi: 10.1517/14728220903449244.
9
Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.接受肿瘤坏死因子阻滞剂治疗患者中的结节病样肉芽肿病：10例
Rheumatology (Oxford). 2009 Aug;48(8):883-6. doi: 10.1093/rheumatology/kep046. Epub 2009 May 7.
10
Development of sarcoidosis during etanercept therapy.依那西普治疗期间结节病的发生
Intern Med. 2008;47(11):1021-5. doi: 10.2169/internalmedicine.47.0602. Epub 2008 Jun 2.
Zotero 插件